论文部分内容阅读
目的探讨联合检测乙型肝炎(下称乙肝)病毒血清标志物两对半定量、乙肝病毒(HBV)DNA定量与前S2抗原对乙肝患者诊断和预后的意义。方法分别使用酶联免疫吸附试验(ELISA)法、荧光定量PCR(FQ-PCR)和化学发光微粒子免疫分析技术(CMIA)对141例乙肝患者的乙肝病毒前S2抗原(Pre-S2)、乙肝病毒DNA(HBV-DNA)、乙肝两对半进行定性和(或)定量检测。结果137例HBsAg阳性患者中Pre-S2阳性119例,HBeAg阳性69例,HBV-DNA阳性84例,阳性率Pre-S2>HBV-DNA>HBeAg。结论联合检测乙肝病毒血清标志物两对半、HBV-DNA定量及Pre-S2,可以更全面地反映临床HBV感染、复制、传染性及抗病毒治疗效果的状况。
Objective To explore the significance of the combined detection of two pairs of semi-quantitative hepatitis B virus (HBV) serum markers, hepatitis B virus (HBV) DNA quantification and pre-S2 antigen in diagnosis and prognosis of hepatitis B patients. Methods 141 cases of hepatitis B virus pre-S2 antigen (Pre-S2), hepatitis B virus (HBV) and hepatitis B virus (HBV) were detected by ELISA, FQ- DNA (HBV-DNA), hepatitis B two pairs of semi-qualitative and (or) quantitative detection. Results Among the 137 HBsAg positive patients, 119 were Pre-S2 positive, 69 were HBeAg positive, 84 were HBV-DNA positive, and the positive rate was Pre-S2> HBV-DNA> HBeAg. Conclusions The combined detection of two-and-a-half serum HBV markers, HBV-DNA quantification and Pre-S2 can more fully reflect the status of clinical HBV infection, replication, infectious and antiviral therapy.